Blood Pressure Control in Treated Hypertensive Patients in Daily Practice of Latvian Family Physicians

Inga Stukena¹, Daiva Asta Apanavičienė², Guntis Bahs¹, Andrejs Kalvelis¹, Vilnis Dzerve³, Baiba Ansmite¹, Oskars Kalejs¹, ⁵, Aivars Lejnieks¹, ⁴
¹Department of Internal Medicine, Riga Stradiuns University, Latvia, ²Sanofi-Aventis Lietuva, Vilnius, Lithuania, ³Research Institute of Cardiology, University of Latvia, Riga, Latvia, ¹Department of Internal Medicine, Riga Eastern Clinical University Hospital, Latvia, ¹Department of Internal Medicine, P. Stradiuns University Hospital, Riga, Latvia

Key words: arterial hypertension; blood pressure control; antihypertensive drugs.

Summary. Background and Objective. The aim of this study was to evaluate blood pressure (BP) control level in treated hypertensive patients in Latvia and to compare their characteristics according to the adequacy of BP control.

Materials and Methods. Family physicians collected information on demographic and clinical characteristics, and current antihypertensive treatment of 455 18–80-year-old patients with essential arterial hypertension treated for 1 or more years. Target BP was defined as values of <140/90 mm Hg for patients with low or moderate cardiovascular risk and <135/85–125/75 mm Hg for patients with high or very high risk. BP was measured in the office setting after a 5-minute rest in a sitting position using a calibrated aneroid sphygmomanometer.

Results. Nearly half of patients (46.2%) attained their target BP. The proportion of patients with effective BP control was higher in the group of low and moderate added cardiovascular risk than in the high and very high added cardiovascular risk group (61.7% vs. 34.4%, P<0.0001). The majority of patients were given two-drug (26.2%) or three-drug (31.6%) combined antihypertensive therapy. Current pharmacological treatment was similar in the patients who attained target BP and in those who did not. Overall, physicians did not modify antihypertensive treatment in 37.9% of patients; such a recommendation was more common among patients with controlled BP. Very few patients (7.4%) who did not attain target BP did not receive recommendations to modify antihypertensive treatment.

Conclusions. The rate of effective BP control was less than 50% and was even worse (34.4%) in patients with high or very high added cardiovascular risk in the present sample of treated hypertensive patients.

Introduction

Using the currently recommended criteria for the diagnosis of arterial hypertension (AH) (mean systolic blood pressure [SBP] of ≥140 mm Hg or mean diastolic blood pressure [DBP] of ≥90 mm Hg or use of antihypertensive medication), the overall prevalence of hypertension in adults in the United States in 1999–2000 was 27% for men and 30% for women (1). National surveys indicate that the prevalence of hypertension in many countries is as high or higher as identified in the United States. Recent estimates suggest that approximately 1 billion adults have hypertension, with the highest prevalence being noted in Eastern Europe and the Latin American/Caribbean region (2). The prevalence of hypertension is 41.8% and 40.5% in Latvian urban and rural populations, respectively (3).

The Seventh Report of the Joint National Comm
economy, only half of all hypertensive patients were treated and only 15% to 20% were controlled to target BP level (6). The reasons for inadequate BP control are complex and arise from a combination of factors related to poor patient adherence to therapy and the way that physicians treat hypertension (noncompliance with the current guidelines, avoidance of combined therapy and nonpharmacologic measures) (7–10).

The main objective of this study was to evaluate BP control level in treated hypertensive patients in Latvia. We also aimed to compare the patients with controlled and uncontrolled BP in terms of their clinical characteristics, prescribed medications, and recommendations for further treatment.

**Materials and Methods**

The protocol of the study was reviewed and approved by the Latvian Independent Ethics Committee for the Investigation of Drugs and Pharmaceutical Products. The study was conducted in accordance with the recommendations adopted by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments.

This was a cross-sectional study. In order to ensure that the data reflect BP control of patients living in urban as well as rural areas, randomly selected family physicians throughout Latvia were asked to participate in the study. A total of 73 family physicians agreed to take part in the study. The regions covered included Aizkraukle, Bauska, Cesis, Daugavpils, Dobele, Jelgava, Kuldiga, Lapmezciems, Liepaja, Limbazi, Ludza, Ogre, Rezekne, Riga, Skrunda, Saldus, Talsi, Tukums, Valmiera, and Ventspils. Every physician had to include at least 6 patients. Every third patient with the diagnosis of hypertension who visited the family physicians on a working day for any reason was asked to take part in the study. In case this patient did not meet the inclusion criteria or refused to participate, the next patient was offered to take part.

A total of 455 patients were recruited between March 2009 and June 2009. The subjects included in the study were 18–80 years old who had a diagnosis of essential AH and had been treated with antihypertensive drugs for at least 1 year. All the patients provided written informed consent. The following exclusion criteria were applied: known secondary hypertension, pregnancy, required hospitalization, and factors that may influence the accuracy of BP measurements (i.e., fever, alcohol or drug addiction, anxiety, restlessness, etc.).

For each patient, the family physician registered the following data into a standardized case report form during a single visit: age, gender, weight, height, waist circumference, duration of AH, concomitant diseases and risk factors, previous antihypertensive treatment, BP, and heart rate. Demographic and medical data were retrieved from patients’ files, while anthropometric parameters (height, weight, and waist circumference) and blood pressure were measured during the study visit. Height (cm) and weight (kg) was measured with indoor clothing and without shoes. BMI was defined as measured weight in kilograms divided by squared height in meters. The waist circumference (cm) was measured at the level of the umbilicus with the participant standing and breathing normally. BP was measured in a seated position after a 5-minute rest using a calibrated mechanical aneroid sphygmomanometer (manufacturer Rudolf Riester GmbH, model Big Ben®). Two measurements were performed. If results of SBP and/or DBP differed by 10 mm Hg or more, the third BP measurement was performed. The mean of 2 or 3 readings was recorded into a case report form. Heart rate (heartbeats per minute) was also measured in a seated position after a 5-minute rest.

Family physicians indicated patients’ target BP according their CV risk and assessed if target BP (<140/90 mm Hg in low and moderate added CV risk or <135/85–125/75 mm Hg in high and very high risk) was achieved. Stratification of CV risk was performed according to the criteria by the ESH/ESC guidelines for the management of arterial hypertension (11) and the Latvian guidelines for hypertension management (12). The stratification was based on records in patients’ files about risk factors:

- Age >55 years for men and >65 years for women;
- Regular smoking;
- Dyslipidemia (total cholesterol >5.0 mmol/L [190 mg/dL] or low-density lipoprotein cholesterol >3.0 mmol/L [15 mg/dL] or high-density lipoprotein cholesterol <1.0 mmol/L [40 mg/dL] for men and <1.2 mmol/L [46 mg/dL] for women or triglycerides >1.7 mmol/L [150 mg/dL]);
- Fasting glucose 5.6–6.9 mmol/L (102–125 mg/dL);
- Abnormal glucose tolerance test;
- Abdominal obesity (waist circumference ≥102 cm for men and ≥88 cm for women);
- Family history of premature CV disease (first-degree relatives with the onset of cardiovascular disease at age <55 years for men and <65 years for women);
- Diagnoses of subclinical target organ damages (electrocardiographic or echocardiographic left ventricular hypertrophy, carotid wall thickening or plaque, carotid-femoral pulse wave velocity >12 m/s, ankle/brachial BP index <0.9, slight increase in plasma creatinine [115–133 mmol/L [1.3–1.5 mg/dL] for men and 107–124 mmol/L [1.2–1.4 mg/dL] for women), low estimated glomerular filtration rate (<60 mL/[min · 1.73 m²]) or creatinine clearance (<60 mL/min), micro-
albuminuria (24-hour urine albumin >30 mg equivalent to >20 μg/min in a morning urine sample or >22 mg/g creatinine for men and >31 mg/g for women in a random urine sample or >20 mg/L using a urine test strip);

- Concomitant diseases (diabetes, ischemic stroke, cerebral hemorrhage, transient ischemic attack, myocardial infarction, angina, coronary revascularization, heart failure, diabetic nephropathy, renal impairment [serum creatinine >133 mmol/L for men or >124 mmol/L for women], proteinuria [≥300 mg/24 h], peripheral artery disease, and advanced retinopathy).

The cluster of 3 of the 5 risk factors (abdominal obesity, altered fasting plasma glucose, BP ≥130/85 mm Hg, low high-density lipoprotein cholesterol level, and high triglyceride level as defined above) indicates the presence of the metabolic syndrome.

According to the above referred guidelines (11, 12), the low added CV risk group comprised patients with the following: 1) normal BP (DBP/SBP, 80–84/120–129 mm Hg) or high normal BP (DBP/SBP, 85–89/130–139 mm Hg) plus 1–2 risk factors; or 2) grade 1 hypertension (DBP/SBP, 90–99/140–159 mm Hg) alone. The moderate added CV risk group comprised patients with the following: 1) normal BP plus ≥3 risk factors or the metabolic syndrome or subclinical organ damage or diabetes; or 2) grade 1 hypertension plus 1–2 risk factors; or 3) grade 2 hypertension (DBP/SBP, 100–109/160–179 mm Hg) with or without 1–2 risk factors. The high added CV risk group included patients with the following: 1) high normal BP or grade 1–2 hypertension plus ≥3 risk factors or the metabolic syndrome or subclinical organ damage or diabetes; or 2) grade 3 hypertension (DBP/SBP, ≥110/180 mm Hg) alone. The very high added CV risk group consisted of patients with the following: 1) established CV or renal disease; or 2) grade 3 hypertension plus 1–3 risk factors or the metabolic syndrome or subclinical organ damage or diabetes.

The main parameter to be evaluated was BP control. BP was considered as controlled if the target BP was achieved according to the assessment of family physicians. The proportion of patients with effective controlled BP was almost 2-fold greater in the group of low or moderate risk in comparison with the group of high or very high added risk (61.7% vs. 34.4%, P<0.0001). BP was controlled (<140/90 mm Hg) in 161 patients (35.4%) as assessed by BP measurements performed during the study visit. The mean BP was similar among patients with different added CV risk (143.2±19.6/85.9±9.9 mm Hg and 144.1±18.5/86.3±10.1 mm Hg in patients with low or moderate risk and high or very high risk, respectively).

In total, 317 patients (69.7%) had at least one concomitant disease. The most frequent comorbid conditions were heart failure, coronary heart disease, and diabetes, each present in more than 30% of patients. The proportion of patients without any concomitant disease in the group of controlled BP was higher than that in the group of uncontrolled BP (35.7% vs. 25.7%). A total of 439 patients (96.3%) had at least one risk factor, with abdominal obesity and dyslipidemia being most prevalent. Among the patients with uncontrolled BP, there were more patients with multiple risk factors (89.4% vs. 80.0%, P<0.05). This group had more patients with metabolic syndrome, dyslipidemia, or abdominal obesity (Table 1).

The results of the final multivariate analysis showed 3 significant predictors of reaching the target BP. Compared with the patients classified as having high or very high added risk, those with low or moderate added risk had a greater chance of reaching targeted BP (odds ratio [OR], 2.42; 95%
confidence interval [CI], 1.73 to 3.39). Lower odds of reaching target BP were associated with the diagnosis of the metabolic syndrome (OR, 0.67; 95% CI, 0.45 to 0.99) or dyslipidemia (OR, 0.59; 95% CI, 0.42 to 0.82).

All patients took antihypertensive drugs for at least 1 year. Diuretics, angiotensin-converting enzyme (ACE) inhibitors, and beta-adrenergic blockers were the most frequent antihypertensive agents; these drugs were used by 305 (67.0%), 300 (65.9%), and 262 patients (57.6%), respectively. Nearly half of the study patients took dihydropyridine (DHP) calcium channel blockers (43.3%). A quarter of patients were treated with angiotensin II receptor antagonists (25.5%). Non-DHP calcium channel blockers, imidazoline receptor blockers, alpha-adrenergic blockers, and other antihypertensive drugs were less common.

Very few patients were administered antihypertensive monotherapy (n=42, 9.2%). One hundred nineteen (26.2%) patients were taking 2 drugs; 144 patients (31.6%), 3 drugs; 110 patients (24.2%), 4 drugs; and 32 patients (7.0%), 5 drugs. Among those who received 3 drugs, the most common combination was DHP calcium channel blocker plus ACE inhibitor plus beta-adrenergic blocker (n=53, 11.7%). The most prevalent combination of 2 antihypertensive drugs was ACE inhibitor plus beta-adrenergic blocker (n=120, 26.4%).

Current pharmacologic management of hypertension was similar in the patients who attained their target BP and those who did not attained their target BP, except the patients with uncontrolled BP who were treated with DHP calcium channel blockers more frequently.

Overall, on the day of study visit, family physicians did not change treatment for 173 patients (38.0%); this decision was more common among patients with controlled BP. For the remaining patients, pharmacological treatment was changed. The majority of patients (N=214, 47.0%) were advised a single treatment correction. Sixty-one patients (13.4%) were offered to change 2 treatment recommendations, while 7 patients (1.5%) were offered 3 changes in their current treatment. An addition of a drug from another class, an increase in a single drug dose, and change of drug class were the more frequent decisions (Table 2).

### Discussion

This study discloses the BP control among patients receiving pharmacologic antihypertensive...
According to the evaluation of family physicians, less than half (46.2%) of patients achieved the recommended BP targets (<140/90 mm Hg in case of low and moderate risk or <135/85–125/75 mm Hg in high and very high risk). The rate of BP control was higher among patients with low or moderate added risk (61.7%) in comparison with patients with high or very high risk (34.4%). According to the results of BP measurements performed during the study visit, 35.4% of patients had a BP of <140/90 mm Hg. These results were confirmed by multivariate analysis. The patients with low or moderate added risk had almost a 2.5-fold greater chance of reaching target BP as compared with those with high or very high added risk (OR, 2.42; 95% CI, 1.73 to 3.39).

Epidemiologic studies carried out in the United States, Canada, and Europe have shown that BP control is inadequate despite pharmacological treatment. In different countries, the percentage of treated hypertensive patients who achieved the recommended BP targets of <140/90 mm Hg in case of low and moderate risk or <135/85–125/75 mm Hg in high and very high risk). The rate of BP control was higher among patients with low or moderate added risk (61.7%) in comparison with patients with high or very high risk (34.4%). According to the results of BP measurements performed during the study visit, 35.4% of patients had a BP of <140/90 mm Hg. These results were confirmed by multivariate analysis. The patients with low or moderate added risk had almost a 2.5-fold greater chance of reaching target BP as compared with those with high or very high added risk (OR, 2.42; 95% CI, 1.73 to 3.39).

Epidemiologic studies carried out in the United States, Canada, and Europe have shown that BP control is inadequate despite pharmacological treatment. In different countries, the percentage of treated hypertensive patients who achieved the recommended BP targets of <140/90 mm Hg in case of low and moderate risk or <135/85–125/75 mm Hg in high and very high risk). The rate of BP control was higher among patients with low or moderate added risk (61.7%) in comparison with patients with high or very high risk (34.4%). According to the results of BP measurements performed during the study visit, 35.4% of patients had a BP of <140/90 mm Hg. These results were confirmed by multivariate analysis. The patients with low or moderate added risk had almost a 2.5-fold greater chance of reaching target BP as compared with those with high or very high added risk (OR, 2.42; 95% CI, 1.73 to 3.39).

Epidemiologic studies carried out in the United States, Canada, and Europe have shown that BP control is inadequate despite pharmacological treatment. In different countries, the percentage of treated hypertensive patients who achieved the recommended BP targets of <140/90 mm Hg in case of low and moderate risk or <135/85–125/75 mm Hg in high and very high risk). The rate of BP control was higher among patients with low or moderate added risk (61.7%) in comparison with patients with high or very high risk (34.4%). According to the results of BP measurements performed during the study visit, 35.4% of patients had a BP of <140/90 mm Hg. These results were confirmed by multivariate analysis. The patients with low or moderate added risk had almost a 2.5-fold greater chance of reaching target BP as compared with those with high or very high added risk (OR, 2.42; 95% CI, 1.73 to 3.39).

A high proportion (90.8%) of patients treated with two or more antihypertensive drugs in the study population shows that Latvian family physicians follow the current national and international guidelines. The widespread use of combined treatment may at least partially explain the relatively high rate of BP control in the study population. However, despite the fact that almost all patients with high or very high added CV risk received combined antihypertensive treatment (91.4%), only one-third of them achieved the target BP. One of the reasons may be the more stringent target BP for patients with high or very high risk (<135/85–125/75 mm Hg). According to the published data from other countries, 30%–60% of hypertensive patients receive monotherapy (15–21, 23, 26, 27). BP control rate in patients receiving monotherapy in Latvia was very low and ranged from 3.8% in patients receiving diuretics to 12.5% in those treated with beta-blockers (3). No information about the proportion of patients receiving monotherapy was provided in this

### Table 2. Current Antihypertensive Treatment and Recommendations for Further Treatment in Patients With Controlled or Uncontrolled Blood Pressure

<table>
<thead>
<tr>
<th>Antihypertensive Treatment and Further Treatment Recommendations</th>
<th>Patients Who Reached Target BP (n=210)</th>
<th>Patients Who Did Not Reach Target BP (n=245)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with ≥ 2 antihypertensive drugs</td>
<td>189 (90.0)</td>
<td>224 (91.4)</td>
</tr>
<tr>
<td>Antihypertensive drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diuretics</td>
<td>143 (68.1)</td>
<td>162 (66.1)</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>130 (61.9)</td>
<td>170 (69.4)</td>
</tr>
<tr>
<td>Beta-adrenergic blockers</td>
<td>117 (55.7)</td>
<td>145 (59.2)</td>
</tr>
<tr>
<td>Calcium channel blockers (DHP)</td>
<td>75 (35.7)</td>
<td>122 (49.8)*</td>
</tr>
<tr>
<td>Angiotensin II receptor antagonists</td>
<td>53 (25.2)</td>
<td>63 (25.7)</td>
</tr>
<tr>
<td>Calcium channel blockers (non-DHP)</td>
<td>33 (15.7)</td>
<td>34 (13.9)</td>
</tr>
<tr>
<td>Other antihypertensive drugs</td>
<td>19 (9.1)</td>
<td>29 (11.8)</td>
</tr>
<tr>
<td>Imidazoline receptor blockers</td>
<td>11 (5.2)</td>
<td>25 (10.2)</td>
</tr>
<tr>
<td>Alpha-adrenergic blockers</td>
<td>12 (5.7)</td>
<td>18 (7.4)</td>
</tr>
<tr>
<td>Recommendations for further treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No treatment changes</td>
<td>155 (73.8)</td>
<td>18 (7.4)*</td>
</tr>
<tr>
<td>Increase in a dose of one drug</td>
<td>9 (4.3)</td>
<td>55 (22.4)*</td>
</tr>
<tr>
<td>Increase in doses of two or more drugs</td>
<td>3 (1.4)</td>
<td>33 (13.5)*</td>
</tr>
<tr>
<td>Change to another drug of the same class</td>
<td>0 (0)</td>
<td>13 (5.3)</td>
</tr>
<tr>
<td>Change to the drug of another class</td>
<td>10 (4.8)</td>
<td>51 (20.8)*</td>
</tr>
<tr>
<td>Addition of a drug of another class</td>
<td>12 (5.7)</td>
<td>113 (46.1)*</td>
</tr>
<tr>
<td>Other recommendations</td>
<td>31 (14.8)</td>
<td>27 (11.0)</td>
</tr>
</tbody>
</table>

Values are number (percentage). BP, blood pressure; ACE, angiotensin-converting enzyme; DHP, dihydropyridine. *P<0.05.
article. Monotherapy even at maximal doses effectively controls BP in less than 50% of hypertensive patients (28); thus, combination therapy is needed for the majority of hypertensive patients. Combination therapy is more effective, and guidelines for the management of hypertension declare the combinations of low dose antihypertensive drugs as a first-choice treatment in patients with high or very high added CV risk (12, 29).

Physicians usually consider the patient nonadherence to pharmacologic and nonpharmacologic treatment as the main barrier to successful hypertension management (6). Information about patient adherence within the framework of this study was not collected; however, other authors reported that only half of Latvian patients (48% in city and 49.7% in village) regularly take prescribed antihypertensive drugs (25).

While interpreting the reasons for relatively high BP control rate found in this study, the possibility of selection bias cannot be excluded, i.e., physicians might be more inclined to enroll patients with better-controlled BP. In order to minimize the selection bias, every third hypertensive patient who visited the family physicians on a working day for any reason was asked to take part in the study.

The comparison of patients’ characteristics revealed that diabetes, metabolic syndrome, dyslipidemia, and abdominal obesity were more frequent among patients with uncontrolled BP. Multivariate logistic regression analysis showed that patients with the metabolic syndrome or dyslipidemia had lower odds of attaining BP target.

As expected, patients with uncontrolled BP were more often recommended to correct the pharmacologic antihypertensive treatment. The most popular decisions were an addition of a drug from another class, an increase in a single drug dose, and change of drug class. Very few patients (7.4%) who did not achieve the target BP were not recommended any treatment recommendations.

Conclusions
In the present sample of treated hypertensive patients, the rate of blood pressure control was less than 50% and was even worse in patients with high or very high added CV risk (34.4%). Since the overwhelming majority of patients with uncontrolled blood pressure received the combination therapy and most of them were recommended some treatment modifications, other unidentified reasons in this study may interfere with the management of hypertension especially among high-risk patients.

Acknowledgments

Statement of Conflict of Interest
The study was financially supported by the Sanoфi-Aventis Latvia Ltd.

References


